PDF herunterladen
CC BY-NC-ND 4.0 · World J Nucl Med 2020; 19(03): 220-223
DOI: 10.4103/wjnm.WJNM_6_19
Original Article

Do fasting or high caloric drinks affect the physiological uptake of fluorine-18 prostate-specific membrane antigen-1007 in liver and bowel?

Kambiz Rahbar
Department of Nuclear Medicine, University Hospital Münster, Münster
,
Ali Afshar-Oromieh
1   Department of Nuclear Medicine, University Hospital of Heidelberg, Germany
2   Department of Nuclear Medicine, Inselspital, University Hospital of Bern, Bern, Switzerland, Switzerland
,
Robert Seifert
Department of Nuclear Medicine, University Hospital Münster, Münster
,
Stefan Wagner
Department of Nuclear Medicine, University Hospital Münster, Münster
,
Michael Schäfers
Department of Nuclear Medicine, University Hospital Münster, Münster
,
Martin Bögemann
3   Department of Urology, University Hospital Münster, Münster
,
Matthias Weckesser
Department of Nuclear Medicine, University Hospital Münster, Münster
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Recently introduced fluorine-18 prostate-specific membrane antigen-1007 (18F-PSMA-1007) for imaging prostate cancer has an intense physiologic liver uptake and biliary excretion. The aim of the present study was to evaluate the effect of different dietary conditions on this physiological uptake. Forty consecutive prostate cancer patients were scanned with 18F-PSMA-1007 positron emission tomography/computed tomography at different dietary conditions. In addition to a blinded read scoring, tracer uptake intensities (standardized uptake values [SUVs]) were measured in the liver and small bowel. There was no significant difference in liver and small-bowel uptake between different patient groups. Wilcoxon signed-rank tests revealed no significant difference of the median mean SUV of the liver or maximum SUV of the horizontal part of the duodenum between different dietary conditions groups. A dietary preparation of patients by fasting or the attempt to clear liver activity by high caloric drinks does not have a significant effect on tracer uptake in the liver or in the small bowel.

Keywords

Positron emission tomography/computed tomography - prostate cancer - prostate-specific membrane antigen-1007

Financial support and sponsorship

Nil.




Publikationsverlauf

Eingereicht: 17. Januar 2019

Angenommen: 14. Februar 2019

Artikel online veröffentlicht:
19. April 2022

© 2020. Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the (68) Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015;42:197-209.
  • 2 Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: Evaluation in 1007 patients. Eur J Nucl Med Mol Imaging 2017;44:1258-68.
  • 3 Rahbar K, Afshar-Oromieh A, Bögemann M, Wagner S, Schäfers M, Stegger L, et al. 18F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with prostate cancer: Biodistribution, tumour detection and activity kinetics. Eur J Nucl Med Mol Imaging 2018;45:1329-34.
  • 4 Rahbar K, Afshar-Oromieh A, Seifert R, Wagner S, Schäfers M, Bögemann M, et al. Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2018;45:2055-61.
  • 5 Giesel FL, Knorr K, Spohn F, Will L, Maurer T, Flechsig P, et al. Detection efficacy of [18F]PSMA-1007 PET/CT in 251 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 2018. pii: jnumed. 118.212233.
  • 6 Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: Biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging 2017;44:678-88.
  • 7 Cardinale J, Schäfer M, Benešová M, Bauder-Wüst U, Leotta K, Eder M, et al. Preclinical evaluation of 18F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging. J Nucl Med 2017;58:425-31.
  • 8 van Dongen AJ, van Rijk PP. Minimizing liver, bowel, and gastric activity in myocardial perfusion SPECT. J Nucl Med 2000;41:1315-7.